

NUVELO INC  
Form 8-K  
February 14, 2005

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of earliest event reported: February 10, 2005**

---

**Nuvelo, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

---

**Delaware**  
**(State or Other Jurisdiction of**  
  
**Incorporation)**

**000-22873**  
**(Commission File Number)**

**36-3855489**  
**(I.R.S. Employer**  
  
**Identification No.)**

**675 Almanor Avenue, Sunnyvale, California 94085**  
  
**(Address of Principal Executive Offices) (Zip Code)**

Edgar Filing: NUVELO INC - Form 8-K

(408) 215-4000

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

(b) On February 10, 2005, Martin Vogelbaum resigned from our Board of Directors. Mr. Vogelbaum stated in his letter of resignation that he was resigning from our Board for personal reasons and not as a result of any disagreement with us or our management. Mr. Vogelbaum served as a member of Variagenics' Board of Directors since June 1997 and became a member of our Board of Directors in February 2003 after our merger with Variagenics.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Nuvelo, Inc.

(Registrant)

By: /s/ Ted W. Love

---

Ted W. Love, M.D.  
Chief Executive Officer and President

Dated: February 14, 2005